Toxic epidermal necrolysis and Stevens-Johnson syndrome

Orphanet Journal of Rare Diseases

Volumn 5, Issue 1, 2010, Pages

  Harr, Thomas ^a   French, Lars E ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOPENICILLIN; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; HLA B ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; INFLIXIMAB; LAMOTRIGINE; MELOXICAM; NEVIRAPINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PIROXICAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALAZOSULFAPYRIDINE; SERTRALINE; STEROID; SULFADIAZINE; SULFADOXINE; SULFAFURAZOLE; SULFAMETHOXAZOLE; TENOXICAM; THALIDOMIDE; UNINDEXED DRUG; VALPROIC ACID; HLA B*5801 ANTIGEN, HUMAN; HLA-B*5801 ANTIGEN, HUMAN;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; BULLOUS PEMPHIGOID; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; GENETIC SUSCEPTIBILITY; HERPES SIMPLEX; HUMAN; INTENSIVE CARE; MYCOPLASMA PNEUMONIA; NONHUMAN; PARANEOPLASTIC PEMPHIGUS; PATHOGENESIS; PEMPHIGUS VULGARIS; PROGNOSIS; RACE DIFFERENCE; REVIEW; SKIN BIOPSY; SKIN DISEASE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ASIAN; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); DRUG TOXICITY; GENETIC PREDISPOSITION; GENETICS; PATHOPHYSIOLOGY;

ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIALS AS TOPIC; DRUG TOXICITY; EPIDERMAL NECROLYSIS, TOXIC; GENETIC PREDISPOSITION TO DISEASE; HLA-B ANTIGENS; HUMANS; STEVENS-JOHNSON SYNDROME;

EID: 78650086690     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-5-39     Document Type: Review

References (112)

1. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. S Bastuji-Garin B Rzany RS Stern NH Shear L Naldi JC Roujeau, Arch Dermatol 1993 129 92 96 10.1001/archderm.129.1.92 8420497
2. Sur un syndrome charactérisé par l'inflammation simultanée de toutes les muqueuses externes coexistant avec une éruption vésiculeuse des quatre membres, non douloureuse et non recidivante. N Fiessinger R Rendu, Paris médical 1917 25 54 58
3. A new eruptive fever associated with stomatitis and ophtalmia; report of two cases in children. AM Stevens FC Johnson, American Journal of Diseases in Children 1922 24 526 533
4. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. A Lyell, Br J Dermatol 1956 68 355 361 10.1111/j.1365-2133.1956.tb12766.x 13374196
5. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. B Rzany O Correia JP Kelly L Naldi A Auquier R Stern, Lancet 1999 353 2190 2194 10.1016/S0140-6736(98)05418-X 10392983
6. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. L La Grenade L Lee J Weaver R Bonnel C Karwoski L Governale A Brinker, Drug Saf 2005 28 917 924 10.2165/00002018-200528100-00008 16180941
7. Toxic epidermal necrolysis in Singapore, 1989 through 1993: incidence and antecedent drug exposure. HL Chan, Arch Dermatol 1995 131 1212 1213 10.1001/archderm.131.10.1212 7574849
8. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. JC Roujeau JP Kelly L Naldi B Rzany RS Stern T Anderson A Auquier S Bastuji-Garin O Correia F Locati, et al. N Engl J Med 1995 333 1600 1607 10.1056/NEJM199512143332404 7477195
9. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. P Saiag E Caumes O Chosidow J Revuz JC Roujeau, J Am Acad Dermatol 1992 26 567 574 10.1016/0190-9622(92)70082- Q 1597543
10. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. A Rotunda RJ Hirsch N Scheinfeld JM Weinberg, Acta Derm Venereol 2003 83 1 9 10.1080/00015550310002611 12636014
11. Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. D Aguiar R Pazo I Duran J Terrasa A Arrivi H Manzano J Martin J Rifa, J Neurooncol 2004 66 345 350 10.1023/B:NEON.0000014538.31561.bc 15015667
12. Stevens-Johnson syndrome in two patients treated with cranial irradiation and phenytoin. F Aydin C Cokluk N Senturk K Aydin MT Canturk AY Turanli, J Eur Acad Dermatol Venereol 2006 20 588 590 10.1111/j.1468-3083.2006.01510.x 16684289
13. Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. S Fournier S Bastuji-Garin H Mentec J Revuz JC Roujeau, Eur J Clin Microbiol Infect Dis 1995 14 558 559 10.1007/BF02113442 7588837
14. Mycoplasma pneumoniae associated with Stevens Johnson syndrome. JM Mulvey A Padowitz M Lindley-Jones R Nickels, Anaesth Intensive Care 2007 35 414 417 17591139
15. Mycoplasma pneumoniae-induced Stevens-Johnson syndrome without skin lesions: fact or fiction? PC Schalock JG Dinulos, J Am Acad Dermatol 2005 52 312 315 10.1016/j.jaad.2004.07.044 15692479
16. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. R Forman G Koren NH Shear, Drug Saf 2002 25 965 972 10.2165/00002018-200225130-00006 12381216
17. Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus? R Mandelcorn NH Shear, J Am Acad Dermatol 2003 48 525 529 10.1067/mjd.2003.107 12664014
18. Stevens-Johnson syndrome associated with azithromycin followed by transient reactivation of herpes simplex virus infection. Y Aihara S Ito Y Kobayashi M Aihara, Allergy 2004 59 118 10.1046/j.1398-9995.2003.00336.x 14674950
19. Toxic epidermal necrolysis: differential diagnosis of an epidermolytic dermopathy in a hematopoietic stem cell transplant recipient. JL Zakrzewski G Lentini U Such A Duerr V Tran S Guenzelmann T Braunschweig UN Riede M Koldehoff, Bone Marrow Transplant 2002 30 331 333 10.1038/sj.bmt.1703624 12209357
20. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. F Lebargy P Wolkenstein M Gisselbrecht F Lange J Fleury-Feith C Delclaux E Roupie J Revuz JC Roujeau, Intensive Care Med 1997 23 1237 1244 10.1007/s001340050492 9470079
21. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. J Revuz D Penso JC Roujeau JC Guillaume CR Payne J Wechsler R Touraine, Arch Dermatol 1987 123 1160 1165 10.1001/archderm.123.9.1160 3632000
22. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. YS Chang FC Huang SH Tseng CK Hsu CL Ho HM Sheu, Cornea 2007 26 123 129 10.1097/ICO. 0b013e31802eb264 17251797
23. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. C Sotozono M Ueta N Koizumi T Inatomi Y Shirakata Z Ikezawa K Hashimoto S Kinoshita, Ophthalmology 2009 116 685 690 10.1016/j.ophtha.2008.12.048 19243825
24. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. LW Yip BY Thong J Lim AW Tan HB Wong S Handa WJ Heng, Allergy 2007 62 527 531 10.1111/j.1398-9995.2006.01295.x 17313402
25. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. S Magina C Lisboa V Leal J Palmares J Mesquita-Guimaraes, Dermatology 2003 207 33 36 10.1159/000070938 12835545
26. Long-term consequences of toxic epidermal necrolysis in children. RL Sheridan JT Schulz CM Ryan JJ Schnitzer D Lawlor DN Driscoll MB Donelan RG Tompkins, Pediatrics 2002 109 74 78 10.1542/peds.109.1.74 11773544
27. Long-term follow-up of patients treated for toxic epidermal necrolysis. A Oplatek K Brown S Sen M Halerz K Supple RL Gamelli, J Burn Care Res 2006 27 26 33 10.1097/01.bcr.0000194268.01514.f8 16566534
28. Reporting adverse drug reactions. JC Roujeau JC Guillaume J Revuz R Touraine, Lancet 1985 2 1244 10.1016/S0140-6736(85)90771-8 2866318
29. Sjogren-like pluriglandular exocrine insufficiency after drug-induced toxic epidermal necrolysis. J Saban JR Pais JL Rodriguez D Boixeda, Postgrad Med J 1991 67 195 197 10.1136/pgmj.67.784.195 2041854
30. Medical genetics: a marker for Stevens-Johnson syndrome. WH Chung SI Hung HS Hong MS Hsih LC Yang HC Ho JY Wu YT Chen, Nature 2004 428 486 10.1038/428486a 15057820
31. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. CB Man P Kwan L Baum E Yu KM Lau AS Cheng MH Ng, Epilepsia 2007 48 1015 1018 10.1111/j.1528-1167.2007.01022.x 17509004
32. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. W Tassaneeyakul S Tiamkao T Jantararoungtong P Chen SY Lin WH Chen P Konyoung U Khunarkornsiri N Auvichayapat K Pavakul, et al. Epilepsia 2010 51 926 930 20345939
33. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. A Alfirevic AL Jorgensen PR Williamson DW Chadwick BK Park M Pirmohamed, Pharmacogenomics 2006 7 813 818 10.2217/14622416.7.6.813 16981842
34. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. N Kaniwa Y Saito M Aihara K Matsunaga M Tohkin K Kurose J Sawada H Furuya Y Takahashi M Muramatsu, et al. Pharmacogenomics 2008 9 1617 1622 10.2217/14622416.9.11.1617 19018717
35. A marker for Stevens-Johnson syndrome.: ethnicity matters. C Lonjou L Thomas N Borot N Ledger C de Toma H LeLouet E Graf M Schumacher A Hovnanian M Mockenhaupt JC Roujeau, Pharmacogenomics J 2006 6 265 268 16415921
36. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. C Lonjou N Borot P Sekula N Ledger L Thomas S Halevy L Naldi JN Bouwes-Bavinck A Sidoroff C de Toma, et al. Pharmacogenet Genomics 2008 18 99 107 10.1097/FPC.0b013e3282f3ef9c 18192896
37. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. SI Hung WH Chung LB Liou CC Chu M Lin HP Huang YL Lin JL Lan LC Yang HS Hong, et al. Proc Natl Acad Sci USA 2005 102 4134 4139 10.1073/pnas.0409500102 15743917
38. Toxic epidermal necrolysis associated with acetaminophen ingestion. A Halevi D Ben-Amitai BZ Garty, Ann Pharmacother 2000 34 32 34 10.1345/aph.19064 10669183
39. Fatal toxic epidermal necrolysis following reexposure to phenytoin: a case report. D Schmidt W Kluge, Epilepsia 1983 24 440 443 10.1111/j.1528-1157. 1983.tb04914.x 6409601
40. Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement. O Correia L Delgado JP Ramos C Resende JA Torrinha, Arch Dermatol 1993 129 466 468 10.1001/archderm.129.4.466 8466217
41. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. L Le Cleach S Delaire L Boumsell M Bagot I Bourgault-Villada A Bensussan JC Roujeau, Clin Exp Immunol 2000 119 225 230 10.1046/j.1365-2249. 2000.01119.x 10606987
42. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. A Nassif A Bensussan L Boumsell A Deniaud H Moslehi P Wolkenstein M Bagot JC Roujeau, J Allergy Clin Immunol 2004 114 1209 1215 10.1016/j.jaci.2004.07. 047 15536433
43. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. WH Chung SI Hung JY Yang SC Su SP Huang CY Wei SW Chin CC Chiou SC Chu HC Ho, et al. Nat Med 2008 14 1343 1350 10.1038/nm.1884 19029983
44. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. I Viard P Wehrli R Bullani P Schneider N Holler D Salomon T Hunziker JH Saurat J Tschopp LE French, Science 1998 282 490 493 10.1126/science.282.5388.490 9774279
45. Keratinocytes constitutively express the Fas antigen that mediates apoptosis in IFN gamma-treated cultured keratinocytes. H Matsue H Kobayashi T Hosokawa T Akitaya A Ohkawara, Arch Dermatol Res 1995 287 315 320 10.1007/BF01105085 7541192
46. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. A Nassif H Moslehi S Le Gouvello M Bagot L Lyonnet L Michel L Boumsell A Bensussan JC Roujeau, J Invest Dermatol 2004 123 850 855 10.1111/j.0022-202X.2004.23439.x 15482470
47. Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. I Viard-Leveugle RR Bullani P Meda O Micheau A Limat JH Saurat J Tschopp LE French, J Biol Chem 2003 278 16183 16188 10.1074/jbc.M212188200 12473659
48. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Murata R Abe H Shimizu, J Allergy Clin Immunol 2008 122 992 1000 10.1016/j.jaci.2008.06. 013 18692887
49. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. P Schneider N Holler JL Bodmer M Hahne K Frei A Fontana J Tschopp, J Exp Med 1998 187 1205 1213 10.1084/jem.187.8.1205 9547332
50. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. R Abe T Shimizu A Shibaki H Nakamura H Watanabe H Shimizu, Am J Pathol 2003 162 1515 1520 12707034
51. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. R Abe N Yoshioka J Murata Y Fujita H Shimizu, Ann Intern Med 2009 151 514 515 19805776
52. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. S Halevy PD Ghislain M Mockenhaupt JP Fagot JN Bouwes Bavinck A Sidoroff L Naldi A Dunant C Viboud JC Roujeau, J Am Acad Dermatol 2008 58 25 32 10.1016/j.jaad.2007.08.036 17919772
53. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. M Mockenhaupt C Viboud A Dunant L Naldi S Halevy JN Bouwes Bavinck A Sidoroff J Schneck JC Roujeau A Flahault, J Invest Dermatol 2008 128 35 44 10.1038/sj.jid.5701033 17805350
54. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. M Mockenhaupt J Messenheimer P Tennis J Schlingmann, Neurology 2005 64 1134 1138 15824335
55. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. P Tennis RS Stern, Neurology 1997 49 542 546 9270593
56. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. F Guibal S Bastuji-Garin O Chosidow P Saiag J Revuz JC Roujeau, Arch Dermatol 1995 131 669 672 10.1001/archderm.131.6.669 7778917
57. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. N Levi S Bastuji-Garin M Mockenhaupt JC Roujeau A Flahault JP Kelly E Martin DW Kaufman P Maison, Pediatrics 2009 123 297 304 10.1542/peds.2008-1923 19153164
58. Hydroxychloroquine-associated, photo-induced toxic epidermal necrolysis. EL Callaly O FitzGerald S Rogers, Clin Exp Dermatol 2008 33 572 574 10.1111/j.1365-2230.2008.02704.x 18477009
59. A case of toxic epidermal necrolysis with lesions mostly on sun-exposed skin. AT Mansur IA Aydingoz, Photodermatol Photoimmunol Photomed 2005 21 100 102 10.1111/j.1600-0781.2005.00149.x 15752129
60. Photo-induced toxic epidermal necrolysis caused by clobazam. P Redondo J Vicente A Espana ML Subira I De Felipe E Quintanilla, Br J Dermatol 1996 135 999 1002 10.1046/j.1365-2133.1996.d01-1111.x 8977728
61. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. R Ball LK Ball RP Wise MM Braun JA Beeler ME Salive, Pediatr Infect Dis J 2001 20 219 223 10.1097/00006454-200102000-00022 11224848
62. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? I Garcia-Doval L LeCleach H Bocquet XL Otero JC Roujeau, Arch Dermatol 2000 136 323 327 10.1001/archderm.136.3.323 10724193
63. Litt's Drug Eruptions and Reactions Manual. JZ Litt, 16 2010 - - Either ISSN or Journal title must be supplied.
64. Severe adverse cutaneous reactions to drugs. JC Roujeau RS Stern, N Engl J Med 1994 331 1272 1285 10.1056/NEJM199411103311906 7794310
65. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. TL Palmieri DG Greenhalgh JR Saffle RJ Spence MD Peck JC Jeng DW Mozingo CJ Yowler RL Sheridan DH Ahrenholz, et al. J Burn Care Rehabil 2002 23 87 96 10.1097/00004630-200203000-00004 11882797
66. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. T McGee A Munster, Plast Reconstr Surg 1998 102 1018 1022 10.1097/00006534-199809040-00014 9734418
67. Outcome of patients with toxic epidermal necrolysis syndrome revisited. I Ducic A Shalom W Rising K Nagamoto AM Munster, Plast Reconstr Surg 2002 110 768 773 10.1097/00006534-200209010-00008 12172137
68. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. SH Kardaun MF Jonkman, Acta Derm Venereol 2007 87 144 148 10.2340/00015555-0214 17340021
69. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Schneck JP Fagot P Sekula B Sassolas JC Roujeau M Mockenhaupt, J Am Acad Dermatol 2008 58 33 40 10.1016/j.jaad.2007.08.039 17919775
70. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. P Wolkenstein J Latarjet JC Roujeau C Duguet S Boudeau L Vaillant M Maignan MH Schuhmacher B Milpied A Pilorget, et al. Lancet 1998 352 1586 1589 10.1016/S0140-6736(98)02197-7 9843104
71. Increased mortality in toxic epidermal necrolysis with thalidomide: corroborating or exonerating the pathogenetic role of TNF-alpha? MR Namazi, Br J Dermatol 2006 155 842 843 10.1111/j.1365-2133.2006.07436.x 16965441
72. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. N Bachot J Revuz JC Roujeau, Arch Dermatol 2003 139 33 36 10.1001/archderm.139.1.33 12533161
73. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. C Prins EW Gelfand LE French, Acta Derm Venereol 2007 87 206 218 17533485
74. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. N Al-Mutairi J Arun NE Osama Z Amr AS Mazen A Ibtesam el B Nazeha el, Int J Dermatol 2004 43 847 851 10.1111/j.1365-4632.2004.02048.x 15533072
75. Toxic epidermal necrolysis: does immunoglobulin make a difference? KM Brown GM Silver M Halerz P Walaszek A Sandroni RL Gamelli, J Burn Care Rehabil 2004 25 81 88 10.1097/01.BCR.0000105096.93526.27 14726744
76. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. E Campione GC Marulli AM Carrozzo MS Chimenti A Costanzo L Bianchi, Acta Derm Venereol 2003 83 430 432 14690337
77. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. C Prins FA Kerdel RS Padilla T Hunziker S Chimenti I Viard DN Mauri K Flynn J Trent DJ Margolis, et al. Arch Dermatol 2003 139 26 32 10.1001/archderm.139.1.26 12533160
78. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. R Shortt M Gomez N Mittman R Cartotto, J Burn Care Rehabil 2004 25 246 255 10.1097/01.BCR.0000124746.33279.86 15273465
79. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. AW Tan BY Thong LW Yip HH Chng SK Ng, J Dermatol 2005 32 1 6 15841652
80. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. JT Trent RS Kirsner P Romanelli FA Kerdel, Arch Dermatol 2003 139 39 43 10.1001/archderm.139.1.39 12533162
81. Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre. R Rajaratnam C Mann P Balasubramaniam JR Marsden SM Taibjee F Shah R Lim R Papini N Moiemen H Lewis, Clin Exp Dermatol 2010 35 8 853 862 10.1111/j.1365-2230.2010.03826.x 20456393
82. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. M Stella A Clemente D Bollero D Risso P Dalmasso, Burns 2007 33 452 459 10.1016/j.burns.2006.08.014 17475410
83. Dose of intravenous immunoglobulin and patient survival in SJS and toxic epidermal necrolysis. JT Trent M Fangchao F Kerdel S Fie LE French p Romanelli RS Kirsner, Expert Review of Dermatology 2007 2 299 303 10.1586/17469872.2.3.299
84. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. K Mangla S Rastogi P Goyal RB Solanki RC Rawal, Indian J Dermatol Venereol Leprol 2005 71 398 400 10.4103/0378-6323.18943 16394480
85. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. P Tristani-Firouzi MJ Petersen JR Saffle SE Morris JJ Zone, J Am Acad Dermatol 2002 47 548 552 10.1067/mjd.2002.127249 12271299
86. Treatment of toxic epidermal necrolysis with cyclosporin A. JM Arevalo JA Lorente C Gonzalez-Herrada J Jimenez-Reyes, J Trauma 2000 48 473 478 10.1097/00005373-200003000-00017 10744287
87. Suprapharmacologic doses of intravenous dexamethasone followed by cyclosporine in the treatment of toxic epidermal necrolysis. R Rai CR Srinivas, Indian J Dermatol Venereol Leprol 2008 74 263 265 10.4103/0378-6323.41379 18583801
88. Early cyclosporine treatment of incipient toxic epidermal necrolysis induced by concomitant use of lamotrigine and sodium valproate. N Hashim D Bandara E Tan A Ilchyshyn, Acta Derm Venereol 2004 84 90 91 10.1080/ 00015550310005906 15040495
89. Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF. E Robak T Robak J Gora-Tybor K Chojnowski B Strzelecka E Waszczykowska A Sysa-Jedrzejowska, J Med 2001 32 31 39 11321886
90. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. L Valeyrie-Allanore P Wolkenstein L Brochard N Ortonne B Maitre J Revuz M Bagot J Roujeau, Br J Dermatol 2010 163 4 847 853 10.1111/j.1365-2133.2010.09863.x
91. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. RE Hunger T Hunziker U Buettiker LR Braathen N Yawalkar, J Allergy Clin Immunol 2005 116 923 924 10.1016/j.jaci.2005.06.029 16210071
92. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. F Meiss P Helmbold N Meykadeh G Gaber W Marsch M Fischer, J Eur Acad Dermatol Venereol 2007 21 717 719 17448012
93. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. D Kamanabroo W Schmitz-Landgraf BM Czarnetzki, Arch Dermatol 1985 121 1548 1549 10.1001/archderm.121.12.1548 4062337
94. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. M Lissia A Figus C Rubino, Br J Plast Surg 2005 58 504 510 10.1016/j.bjps.2004.12.007 15897036
95. A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis. H Yamada K Takamori H Yaguchi H Ogawa, Ther Apher 1998 2 153 156 10.1111/j.1744-9987.1998.tb00094.x 10225718
96. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? A Furubacke G Berlin C Anderson F Sjoberg, Intensive Care Med 1999 25 1307 1310 10.1007/s001340051063 10654219
97. Cyclophosphamide in the treatment of toxic epidermal necrolysis. NG Frangogiannis I Boridy M Mazhar R Mathews S Gangopadhyay T Cate, South Med J 1996 89 1001 1003 10.1097/00007611-199610000-00015 8865797
98. Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects. MC Heng SG Allen, J Am Acad Dermatol 1991 25 778 786 10.1016/S0190-9622(08)80969-3 1802900
99. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. LW Yip BY Thong AW Tan LW Khin HH Chng WJ Heng, Eye (Lond) 2005 19 846 853 15389280
100. Hypopharyngeal stenosis and dysphagia complicating toxic epidermal necrolysis. JE Barrera AD Meyers EC Hartford, Arch Otolaryngol Head Neck Surg 1998 124 1375 1376 9865761
101. Esophageal stricture secondary to drug-induced toxic epidermal necrolysis. TE Herman DC Kushner RH Cleveland, Pediatr Radiol 1984 14 439 440 10.1007/BF02343438 6504607
102. Two cases of toxic epidermal necrolysis caused by delayed hypersensitivity to beta-lactam antibiotics. A Romano M Di Fonso D Pocobelli L Giannarini A Venuti A Garcovich, J Investig Allergol Clin Immunol 1993 3 53 55 8281332
103. Delayed hypersensitivity in ampicillin-induced toxic epidermal necrolysis. H Tagami K Tatsuta K Iwatski M Yamada, Arch Dermatol 1983 119 910 913 10.1001/archderm.119.11.910 6639111
104. [Toxic epidermal necrolysis following dorzolamide eyedrops]. VM Asensio-Sanchez, An Med Interna 2008 25 47 48 18751332
105. [Polymorphous bullous erythema and trihexiphenidyl (or why police questioning is not always the most productive method)]. JL Schmutz A Barbaud P Trechot, Ann Dermatol Venereol 2007 134 899 10.1016/S0151-9638(07)92849-5 18033085
106. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. P Wolkenstein O Chosidow ML Flechet O Robbiola M Paul L Dume J Revuz JC Roujeau, Contact Dermatitis 1996 35 234 236 10.1111/j.1600-0536.1996.tb02364.x 8957644
107. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. WJ Pichler J Tilch, Allergy 2004 59 809 820 10.1111/j.1398-9995.2004.00547.x 15230812
108. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Y Kano K Hirahara Y Mitsuyama R Takahashi T Shiohara, Allergy 2007 62 1439 1444 10.1111/j.1398-9995.2007.01553.x 17983378
109. CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. A Beeler L Zaccaria T Kawabata BO Gerber WJ Pichler, Allergy 2008 63 181 188 18005225
110. In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. A Zawodniak P Lochmatter D Yerly T Kawabata M Lerch N Yawalkar WJ Pichler, Allergy 2009 65 3 376 84 10.1111/j.1398-9995.2009.02180.x 19793058
111. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. S Bastuji-Garin N Fouchard M Bertocchi JC Roujeau J Revuz P Wolkenstein, J Invest Dermatol 2000 115 149 153 10.1046/j.1523-1747.2000.00061.x 10951229
112. Serum lactate dehydrogenase is a novel marker for the evaluation of disease severity in the early stage of toxic epidermal necrolysis. SJ Yun MS Choi MS Piao JB Lee SJ Kim YH Won SC Lee, Dermatology 2008 217 254 259 10.1159/000148255 18667824